MedTrace Logo

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

NCT05800366 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-03-05

No results posted yet for this study

Summary

The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma.

The names of the treatment interventions involved in this study are:

* Glofitamab (T-cell bispecific antibody)
* Polatuzumab (antibody-drug conjugate)
* R-CHP (a chemotherapy regimen comprised of Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, and Prednisone)

Conditions

  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG

Prednisone

Per standard care, orally

DRUG

Glofitamab

human IgG1-bispecific antibody, via IV infusion

DRUG

Polatuzumab

an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion

DRUG

Rituximab

Per standard care, via IV infusion

DRUG

Doxorubicin Hydrochloride

Per standard care, via IV infusion

DRUG

Cyclophosphamide

Per standard care, via IV infusion

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Jennifer Crombie, MD

    lead OTHER

Principal Investigators

  • Jennifer Crombie, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-06
Primary Completion
2026-09-15
Completion
2029-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05800366 on ClinicalTrials.gov